LADR Platform
Various Cancers
PreclinicalResearch
Key Facts
About LadRx
LadRx is a clinical-stage oncology company focused on improving cancer chemotherapy through its proprietary linker-activated drug release (LADR) platform. Its mission is to develop safer, more effective treatments by targeting the release of potent chemotherapeutics within the acidic tumor microenvironment. The company's strategy hinges on advancing its lead asset, aldoxorubicin, for soft tissue sarcoma and exploring its potential in other malignancies, while navigating the significant capital and execution risks inherent in late-stage drug development. As a micro-cap public entity, LadRx operates with a lean structure, deriving its value from its clinical IP and platform technology.
View full company profileTherapeutic Areas
Other Various Cancers Drugs
| Drug | Company | Phase |
|---|---|---|
| Oncology/Immuno-oncology Portfolio | MSD | Phase III/Commercial |
| Bevacizumab Biosimilar | Dr. Reddy's Laboratories | Approved |
| Zip-Code Library for Oncology | Kodikaz Therapeutic Solutions | Pre-clinical |
| Proprietary RLT Pipeline | Affibody | Not Specified (Preclinical-Phase 2) |
| Preclinical ASO Portfolio | Isarna Therapeutics | Preclinical |
| SPACE-GM Microenvironment Analysis | Enable Medicine | Research |
| Oncology Program(s) | CIS Pharma | Pre-clinical |
| Max Access Solutions (with The Max Foundation) | Tanner Pharma Group | N/A (Donation/Distribution Program) |
| Oncology Immunotherapy Programs | Therapeutic Solutions International | Pre-clinical |
| CPA Platform in Oncology | InnoSIGN | Development |
| Oncology Services | Transcure Bioservices | Preclinical |
| Oncology R&D | Orion Pharma | Not Specified |